There is no available information or any published study assessing in a comprehensive way the health risks associated with α-PVP, namely chronic and acute toxicity, but observations in animals suggest similar effects to those observed in other stimulants. Adverse symptoms observed in humans include tachycardia, hyperthermia, diaphoresis, agitation, convulsions or seizures, confusion and aggression. Data from non-clinical studies suggest that α-PVP may have an abuse liability and possibly a dependence potential in humans.
Recital 5, Decision_act (EU) 2016/1070
In forcesince 27 Jun 2016